A n infected mother can transmit HIV to her child during pregnancy, delivery, or breast feeding. Antiviral treatment of mother and child, 1 2 caesarean section, 3 and avoidance of breast feeding 4 have reduced transmission rates among women in Europe to 0%-2%. [5] [6] [7] Only women who know their HIV status before delivery can benefit from all these interventions.
The impact of antenatal screening in preventing HIV infection in children depends on the prevalence of undetected HIV infection among childbearing women, the uptake and detection rate of testing, the rate of terminations, the maternal transmission rate with interventions, and the compliance with interventions. Only a randomised trial of screened and unscreened populations would give an unbiased estimate of this impact. Lacking such a trial, researchers have modelled the impact using data on these factors from randomised trials and observational studies. [8] [9] [10] Since 1987, pregnant women in Norway have routinely been offered HIV testing. The original purpose was to give infected women the option of terminating the pregnancy to avoid the risk of giving birth to a child who would be orphaned, get AIDS, or both. 11 As new, effective interventions have become available, they have been offered to infected women. We use routinely collected surveillance data to compare the actual impact of the antenatal HIV screening programme in Norway during the first 12 years with the expected outcome after no screening.
METHODS
Both antenatal care and legal abortions are freely available to pregnant women in Norway. Blood for the mandatory syphilis test and the voluntary HIV test is usually taken at the booking visit or during preabortion counselling around weeks 8-14 of pregnancy. Twenty three laboratories perform initial HIV antibody testing with commercially available standard enzyme linked immunosorbent assay (ELISA) kits. A new blood sample is requested if the sample is reactive. If the second sample is also reactive in ELISA, it is sent to one of five reference laboratories for renewed ELISA testing and confirmatory testing by western blotting.
We used data from two routine data collection systems.
(1) Monthly summary reports from the 23 laboratories that perform HIV testing gave us the numbers in the following groups.
• Pregnant women tested with the mandatory test for syphilis-that is, the population eligible for HIV screening • Pregnant women tested for HIV antibodies • Women who were requested to send a new sample because of an indeterminate result of the HIV test • Women with a confirmed positive HIV test.
(2) From the mandatory, anonymous surveillance system for HIV infection, which has a 100% coverage and almost complete information on cases 12 we extracted data in April 2002 on the following two groups.
• Women diagnosed in the screening programme between its start in September 1987 and December 1999 • Vertically infected children born in Norway between March 1988 and June 2000 (when women screened between September 1987 and December 1999 gave birth). The expected number had there been no screening programme is the sum of the observed number of children born to women not detected by the programme, and the number of screen positive women (minus the estimated proportion who had already planned legal abortion) multiplied by the cumulative transmission risk during pregnancy, delivery, and breast feeding in the absence of interventions. We set this risk at 31% on the following basis. In most European cohort studies, transmission risk with vaginal delivery and no zidovudine prophylaxis has ranged between 15.5% and 20%. 5-7 13 14 We chose 17.5%. In Norway, 97% of women breast feed for 1 month after delivery. They would have an additional risk of 14% of transmitting HIV to their baby. 4 15 The relative preventive impact is 1 minus the ratio observed: expected, and the absolute impact is the expected minus the Abbreviations: ELISA, enzyme linked immunosorbent assay observed rate. We calculated exact 95% CIs for the ratio 16 and asymptotic 95% CIs for the difference. 17 
RESULTS
In the period September 1987 to December 1999, 96% of 961 000 eligible pregnant women had an antenatal HIV screening test (table 1) . Of the tested women 1/1000 had an indeterminate test result and were asked to submit a new sample. Forty six women had a confirmed positive HIV test in two consecutive blood samples. The prevalence was thus 5.0/100 000 cases of previously undiagnosed women screened for HIV infection. Twenty seven were African or south east Asian women infected before immigration to Norway. The other 19 women had a wide range of exposures. Six were immigrant women infected while living in Norway.
Between March 1988 and June 2000, there were 739 000 live births in Norway, of whom nine (1.2/100 000) acquired HIV from their mother during pregnancy, birth, or breast feeding. Among the nine mothers, three were known to be HIV positive and had chosen not to be screened, two had chosen to continue the pregnancy after being diagnosed by antenatal screening, and four seroconverted after screening (table  2) .
Without screening, we would have expected 18 childrenthat is, 2.5/100 000 (11 instead of only two born to the 46 women detected by the programme plus the three plus four other children already mentioned). The absolute impact of the screening programme was 1.3 infected children prevented in 100 000 women screened (95% CI −0.1 to 2.7). The relative preventive impact was 51% (−15% to 81%).
In the period 1987-99, 25 pregnant women were diagnosed with HIV infection for reasons other than antenatal screening.
DISCUSSION
During more than 12 years of antenatal HIV screening in Norway, 46 women have had their HIV infection detected as a result of the programme and nine cases of HIV infection in children have been prevented. Most cases of HIV infection occurred in children of mothers who had not been screened because they knew their serostatus or mothers who had seroconverted late in pregnancy.
The study is subject to some limitations. Firstly, the anonymous surveillance system does not allow us to track pregnancies of HIV positive women. Thus, we do not know the consequences of the positive screening result for the 46 womenthat is, whether they terminated the pregnancy or gave birth with or without interventions. All we know is that only two of them compared with the expected 11 had a live child born with HIV infection. Thus, the programme may be seen to have prevented nine cases, although that prevention may have been through termination of at risk pregnancies.
Secondly, we cannot rule out that some infected children born in later years have not yet been diagnosed. However, we find this unlikely as the youngest children are now almost 2 years old and should show signs of immunodeficiency. Thirdly, the impact is influenced by the prevalence of undetected HIV infection among childbearing women. In Norway, voluntary HIV testing occurs often outside the screening programme, especially in the high prevalence groups of drug injectors and African immigrants. 12 18 Thus, the very few HIV cases among young women in Norway 19 have usually been detected before pregnancy and few cases remain to be detected by the screening programme. This, of course, limits the absolute impact of the screening programme in Norway today. Changes in incidence of HIV and testing frequencies may change the situation and make the programme more valuable.
Two women seroconverted after the screening, were not diagnosed before birth, and had children infected with HIV. These two occurrences in more than 12 years hardly justify introducing a second test later in pregnancy. However, providers should take care to counsel and repeatedly test those women thought to be at continued risk. Moving the HIV test closer to the time of delivery is not an option as this would remove the woman's option of terminating the pregnancy if she was found to be HIV positive.
We know of no false negative screening tests. The false positive rate is 0.1%. Although these women were retested before they were told the final result, the procedure may have caused severe anxiety.
There has been no randomised trial of antenatal HIV screening and its actual performance in preventing HIV in children remains uncertain. This study suggests that in a very low prevalence population, the absolute impact of screening is low and a policy of offering HIV testing to selected women only may be an alternative. 
